Feed / SLS

SELLAS Life Sciences Group, Inc

SLS

Healthcare · 13.78 +9.0% today

Participation confirmed · construction unavailableMarket checked 20 Aug, 09:30 GMT-4

Jodie situation report

SELLAS Life Sciences Group, Inc's move is being confirmed by its market group.

No new filing conclusion is available. 28 of 31 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.

Company+9.0% todayVolume comparison unavailable
Market group28 of 31 activeBiotechnology Therapeutics · active
Disclosed network0 of 6 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 21 of 31 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NRIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 10 of 31 members or fewer.

Watch this read

Who this business touches

The relationships behind SLS

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

MRKMerck & Company, Inc.partnerMar 19, 2026

GPS Combination Therapy with Checkpoint Inhibitors Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab Given the potential immunobiologic and pharmacodynamic synergy between GPS and an immune check-point inhibitor (e.g., PD-1 inhibitor), we ente…

AZNAstraZeneca PLCcompetitorMar 19, 2026

Key Attributes Higher selectivity : In preclinical studies, SLS009 has demonstrated higher selectivity for CDK9 than other members of the human kinome when compared to other non-oral CDK9 inhibitors in clinical development in the United States for hematologic…

BMYBristol-Myers Squibb CompanycompetitorMar 19, 2026

Principal competitors for AML broadly include companies with currently marketed products, such as AbbVie/Genentech (Venclexta), Pfizer (Mylotarg), Daiichi-Sankyo (Vanflyta), Rigel Pharmaceuticals (Rezlidhia), Syndax Pharmaceuticals (Revumenib) and Bristol Mye…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

SLS is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.